Daftar Pustaka
1. Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1-100.
2. Butt AA, Dargham SR, Chemaitelly H, al Khal A, Tang P, Hasan MR, et al.
Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in Qatar. JAMA Intern Med. 2022;182(2):197–205.
3. Mascellino MT, Timoteo F, Angelis M, Oliva A. Overview of the main anti- sars-cov-2 vaccines: Mechanism of action, efficacy and safety. Infect Drug Resist. 2021;14:3459–76.
4. CNN (2021) Sumbar Kedatangan 145 ribu dosis vaksin Moderna untuk umum. https : // www . cnnindonesia . com / nasional /20210816203838- 20681305 / sumbar kedatangan 145 ribu dosis vaksin moderna untuk umum- Diakses pada 17 Maret 20222.
5. Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422.
6. AL Kaabi N, Zhang Y, Xia S, Yang Y, al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID- 19 infection in Adults: A randomized clinical trial. JAMA. 2021;326(1):35- 45.
7. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
International Journal of Infectious Diseases. Int J Infect Dis. 2022; 141:252–
60.
8. Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al.
Risk factors for severe and critically ill COVID-19 patients: A review.
Allergy: J Allergy Clin Immunol. 2021;71:428–55.
9. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al.
Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069- 76.
10. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al.
Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-54.
11. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al.
Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-54.
12. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.
BMC Infect Dis;2021(21):855.
13. Maier HJ, Bickerton E, Britton P. Coronaviruses methods and protocols methods in molecular biology 1282. Available from:
http://www.springer.com/series/7651
14. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID- 19. Nat Rev Microbiol. 2021; 19(3):141-54.
15. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565–74.
16. Jha N, Jeyaraman M, Rachamalla M, Ojha S, Dua K, Chellappan D, et al.
Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches. Immuno. 202;1(1):30–66.
17. Huang Y, Yang C, Xu X feng, Xu W, Liu S wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Vol. 41, Acta Pharmaco Sin. 2020; 41(9):1141- 49.
18. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020;10(2020):102–8.
19. Chaudhry F, Lavandero S, Xie X, Sabharwal B, Zheng YY, Correa A, et al.
Manipulation of ACE2 expression in COVID-19. Open Heart 2020;7:e001424.
20. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun.
2020;109:102433.
21. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin- converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422.
22. Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the
delta variant B.1.617.2 COVID-19. Clin Pract .2021;11(4):778–84.
23. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.
24. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 2021;97:312–320.
25. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. Postgrad Med J.2021;97:312–320.
26. Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathogens.
2013; 9(1).
27. Baratawidjaja K, Rengganis I. Imunologi dasar edisi 12. Jakarta: Badan Penerbit FK UI; 2018. 376–383.
28. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Immunol. 2020;38(1):1–9.
29. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955.
30. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
31. Kementrian Kesehatan Republik Indonesia (Indonesia). Keputusan menteri kesehatan republik indonesia nomor HK.01.07/MENKES/413/2020 tentang pedoman pencegahan dan pengendalian coronavirus disease 2019 (COVID- 19). 2020.
32. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infec Dis. 2020;94:91–5.
33. Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J. Clin. Virol. 2020;1:128.
34. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?. Eur J Radiol.
2020;126:108961.
35. Mahdi AO, Parham M, Ehsaneh K, Sukran K et al. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2(COVID-19) during the outbreaj period. Infez Med. 2020;28(2):153-165.
36. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman Tatalaksana COVID-19 edisi 3 tim editor Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020. Diakses pada 15 Maret 2022.
37. Izcovich A, Ragusa MA, Tortosa F, Marzio MAL, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One; 15(11): e0241955.
38. Bellou V, Tzoulaki I, van Smeden M, Moons KGM, Evangelou E, Belbasis L. Prognostic factors for adverse outcomes in patients with COVID-19: A field-wide systematic review and meta-analysis. Eur Respi J. 2022; 5(59:
2002964.
39. de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, et al. Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine. 2021; 67:103378.
40. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al.
Causes of death and comorbidities in hospitalized patients with COVID-19.
Sci Rep. 2021; 11(1): 4263
41. Lurie N, Savile M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. NEJM. 2020;382(32):1969-1973.
42. Pavel STI, Yetiskin H, Uygut MA, Aslan AF, Aydın G, İnan Ö, et al.
Development of an inactivated vaccine against SARS CoV-2. Vaccines.
2021;9(11):1266.
43. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine
technology. Vol. 65, Curr Opin Immunol. 2020; 65: 14-20.
44. Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines. 2014. 14(2): 221–34.
45. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4): 418-23.
46. Zhou X, Jiang X, Qu M, Aninwene GE, Jucaud V, Moon JJ, et al.
Engineering antiviral vaccines. ACS Nano. 2020; 14(1): 12370–89.
47. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020; 20(10): 581–2.
48. Nov (2021). What the Novavax vaccine mean for the global fight against COVID-19. https://www.vox.com/22533090/novavax-vaccine-trial-covid- 19-coronavirus-variants. Diakses pada 20 Maret 2021.
49. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al.
Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med.
2021 ;385(13):1172–83.
50. Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines : Immunological mechanism and beyond. Vaccines. 2021;9(2):1–20.
51. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–84.
52. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.
Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–84.
53. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al.
BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23.
54. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al.
Morbidity and mortality weekly report effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years-COVID-NET, 13 states. 2021;70(32):1088-1093.
55. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on
covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ. 2021;37:1088.
56. Satuan Tugas Penanggualangan COVID-19 (2022). Jenis kelamin COVID- 19. https://covid-19.go.id/peta-sebaran - Diakses pada 12 Desember 2022.
57. Kurniyanto, Setianegari Y, Kurniaty L, Luhulima DEJ, Utomo BSR, Langi LA, et al. Factors associated with death and ICU referral among COVID-19 patients hospitalized in the secondary referral academic hospital in East Jakarta, Indonesia. J Clin Virol Plus. 2022;2(2):100068.
58. Mahata LE, Lailani M, Rezvi S, Putra SP, Putra AE. Age and sex differences in COVID-19 clinical symptom: analysis of 19,588 Indonesian cases. Open Access Maced J Med Sci. 2022;10:643–6.
59. Conti P, Younes A. Coronavirus cov-19/sars-cov-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents.
2020;34(2):339–43.
60. Pinheiro I, Dejager L, Libert C. X-chromosome-located microRNAs in immunity: Might they explain male/female differences?: The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. BioEssays. 2011;33(11):791–802.
61. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine.
2021;71(1):3–8.
62. Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: Sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020;116(14):2197–206.
63. Achidsti A, Sari OK, Ratnasari DP, Ningsih NS, Widyaningrum AR, Maji JS, et al. Women’s resilience and vulnerability in facing COVID-19 in DKI Jakarta and East Java. Populasi. 2021;28(2):96.
64. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Augello M, Mondatore D, et al. Female gender is associated with long COVID syndrome : a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611
65. Satuan Tugas Penanggualangan COVID-19 (2022). Usia COVID-19.
https://covid-19.go.id/peta-sebaran - Diakses pada 12 Desember 2022.
66. Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes;
lessons learned one year into the pandemic: A systematic review. World J Crit Care Med. 2021 Jul 9;10(4):132–50.
67. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2:
A prospective cohort study. Eur Respir J. 2020;55(5).
68. Sopyan Andy, Maiza Lilik, Sukesih. Tigkat pendidikan dan pengetahuan dengan perilaku pencegahan Covid-19 pada masyarakat. Universty Res Colloqium. 2021;290–6.
69. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empower Heal. 2020;3(2):77.
70. Satuan Tugas Penanggualangan COVID-19 (2022). Penyakit penyerta COVID-19. https://covid-19.go.id/peta-sebaran - Diakses pada 12 Desember 2022.
71. Starke KR, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: A systematic review with meta-analysis. BMJ Glob Heal. 2021;6(12):1–12.
72. Satuan Tugas Penanggualangan COVID-19 (2022). Vaksinasi COVID-19.
https://covid-19.go.id/peta-sebaran - Diakses pada 12 Desember 2022.
73. Indra B, Lipoeto NI, Hardisman H, Putra AE, Tjong DH, Rahman S, et al.
The severity of COVID-19 and its correlation with inflammation biomarkers.
Open Access Maced J Med Sci. 2022;10:911–5.
74. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–12.
75. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid- 19. N Engl J Med. 2021;384(23):2187–201.
76. Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, et al. Effectiveness of
inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the Delta variant: Real World Study and Evidence
— China, 2021. China CDC Wkly. 2022;4(4):57–65.
77. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, Mcneal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376.
78. Li M, Liu Q, Wu D, Tang L, Wang X, Yan T, et al. Association of COVID- 19 vaccination and clinical severity of patients infected with Delta or Omicron variants — China, May 21, 2021–February 28, 2022. China CDC Wkly. 2022;4(14):293–7.
79. Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(5):1770–6.
80. Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, et al.
Analysis of COVID-19 incidence and severity among adults vaccinated with 2-Dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open. 2022;5(8):E2228900.
81. Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, et al.
COVID-19: vaccination vs. hospitalization. Infection. 2022;50(3):747–52.
82. Arie Zainul Fatoni RR. Acute Respiratory Distress Syndrome (ARDS) pada Pneumonia COVID-19. Journal of Anaesthesia and Pain. 2021;2(1):11–24..
83. Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol. 2021;18(10):2307–12.
84. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol.
2022;23(2):186–93.
85. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47–56.
86. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med.
2020;76:14–20.
87. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Neshin SAS, Khatami A, et al. Effectiveness of covid-19 vaccines against delta (B.1.617.2) variant: A systematic review and meta-analysis of clinical studies. Vaccines. 2022;10(1).
88. Vassallo M, Clement N, Lotte L, Manni S, Sindt A, Bertrand PM, et al.
Prevalence and main clinical characteristics of fully vaccinated patients admitted to hospital for Delta variant COVID-19. Front Med. 2022 9:809154.
89. Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al.
Associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US States, January 2021 to April 2022. JAMA Intern Med. 2022;182(10):1071–81.
90. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on COVID-19 outbreaks in the United States.
Clin Infect Dis. 2021;73(12):2257-2264.
91. Lorenzoni G, Rosi P, De Rosa S, Ranieri VM, Navalesi P, Gregori D.
COVID-19 Vaccination status among adults admitted to intensive care units in Veneto, Italy. JAMA Netw Open. 2022;5(5):10–2.
92. Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, Seppälä E, Golestani K, Kvåle R, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect.
2022;28(6):871–8.
93. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman Tatalaksana COVID-19 edisi 3 tim editor Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020. Diakses pada 15 Maret 2022.
94. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global
impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–302.
95. Sevinc SA, Metin S, Basi NB, Ling J, Cinar AS, Oba S. Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival. Epidemiol Infect. 2022;150:1–6.
96. Ahmad Malik J, Ahmed S, Shinde M, Almermesh MHS, Alghamdi S, Hussain A, et al. The impact of COVID-19 on comorbidities: a review of recent updates for combating it. Saudi J Biol Sci. 2022;29(5):3586–99.
